{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T16:03:15Z","timestamp":1740153795651,"version":"3.37.3"},"reference-count":47,"publisher":"Wiley","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Hematology"],"published-print":{"date-parts":[[2012]]},"abstract":"<jats:p><jats:italic>JAK2<\/jats:italic>is a tyrosine kinase gene that plays an essential role in the development of normal haematopoiesis. Hyperactivation of<jats:italic>JAK2<\/jats:italic>occurs in myeloproliferative neoplasms by different mechanisms. As a consequence,<jats:italic>JAK2<\/jats:italic>inhibitors have been designed to suppress the cytokine signalling cascade caused by the constitutive activation of<jats:italic>JAK2<\/jats:italic>. In clinical trials,<jats:italic>JAK2<\/jats:italic>inhibitors are efficient in decreasing spleen size, controlling clinical symptoms, and improving quality of life in patients with myeloproliferative neoplasms. However,<jats:italic>JAK2<\/jats:italic>inhibitors are unable to target uncommitted hematopoietic progenitors responsible of the initiation of the myeloproliferative disease. It is expected that, in order to cure the myeloproliferative disease,<jats:italic>JAK2<\/jats:italic>inhibitors should be combined with other drugs to target simultaneously different pathways and to target the initiator hematopoietic cell population in myeloproliferative disorders. Taking advantage of the inhibition of the cytokine cascade of<jats:italic>JAK2<\/jats:italic>inhibitors, these compounds are going to be used not only to treat patients with hematological neoplasms but may also be beneficial to treat patients with rheumatoid arthritis or other inflammatory diseases.<\/jats:p>","DOI":"10.1155\/2012\/535709","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T16:01:43Z","timestamp":1329408103000},"page":"1-6","source":"Crossref","is-referenced-by-count":3,"title":["<i>JAK2<\/i>Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms"],"prefix":"10.1155","volume":"2012","author":[{"given":"Mar","family":"Bellido","sequence":"first","affiliation":[{"name":"Department of Hematology, Erasmus University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3566-5016","authenticated-orcid":true,"given":"Peter A. W.","family":"te Boekhorst","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-4-41"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00416-8"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0382"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4575"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1000500"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-010-0126-z"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.179"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-210039"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015826"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01428.x"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403712"},{"issue":"5894","key":"12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/300765a0","volume":"300","year":"1982","journal-title":"Nature"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02127.x"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08249.x"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2010.479"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81167-8"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065202"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270108"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0604902103"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-131664"},{"issue":"6","key":"23","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","volume":"24","year":"2010","journal-title":"Leukemia"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2009.10.014"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1038\/nature08448"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-222133"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.2174\/092986710794182953"},{"journal-title":"American Society of Hematology: Education Program","first-page":"636","year":"2009","key":"28"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002028"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214957"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.56"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.02.009"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009746"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.8021"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-223727"},{"key":"36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083402"},{"key":"37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-246363"},{"key":"38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441409"},{"issue":"6","key":"39","first-page":"394","volume":"13","year":"2010","journal-title":"IDrugs"},{"issue":"24","key":"40","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.4161\/cc.5.24.3573","volume":"5","year":"2006","journal-title":"Cell Cycle"},{"key":"41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.05.015"},{"key":"42","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2010.03.005"},{"key":"43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-258772"},{"key":"44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-4002"},{"key":"45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-325589"},{"key":"46","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.254"},{"key":"47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08467.x"}],"container-title":["Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/ah\/2012\/535709.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ah\/2012\/535709.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ah\/2012\/535709.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T10:23:18Z","timestamp":1497954198000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.hindawi.com\/journals\/ah\/2012\/535709\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":47,"alternative-id":["535709","535709"],"URL":"https:\/\/doi.org\/10.1155\/2012\/535709","relation":{},"ISSN":["1687-9104","1687-9112"],"issn-type":[{"type":"print","value":"1687-9104"},{"type":"electronic","value":"1687-9112"}],"subject":[],"published":{"date-parts":[[2012]]}}}